A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis
- 30 April 1994
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 30 (4) , 597-602
- https://doi.org/10.1016/s0190-9622(94)70068-0
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Papaverine Hydrochloride in the Treatment of Atopic Dermatitis: A Double-Blind, Placebo-Controlled Crossover Clinical Trial to Reassess Safety and EfficacyDermatology, 1991
- Thymopentin therapy reduces the clinical severity of atopic dermatitisJournal of Allergy and Clinical Immunology, 1990
- IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2.Proceedings of the National Academy of Sciences, 1988
- Immunoglobulin E and Immunoglobulin G Subclass Distribution in vivo and Relationship to in vitro Generation of Interferon-Gamma and Neopterin in Patients with Severe Atopic DermatitisInternational Archives of Allergy and Immunology, 1988
- CHANGES IN THE REPORTED PREVALENCE OF CHILDHOOD ECZEMA SINCE THE 1939-45 WARThe Lancet, 1984
- Atopic dermatitisJournal of the American Academy of Dermatology, 1982
- A Synthetic Pentapeptide with Biological Activity Characteristic of the Thymic Hormone ThymopoietinScience, 1979
- Thymopoietin-induced acquisition of responsiveness to T cell mitogensCellular Immunology, 1975
- Chemical synthesis of a peptide fragment of thymopoietin II that induces selective T cell differentiationCell, 1975
- Immunoglobulin E in DermatosesArchives of Dermatology, 1969